The antiphospholipid syndrome (APS) is diagnosed by the occurrence of thrombosis and/or specific pregnancy morbidity. However, the diagnosis of APS is not easy and is hampered by several problems including high prevalence of clinical symptoms and high variability between different assays resulting in a high false-positive rate. Currently APS can be diagnosed for example by detecting anti-β2-glycoprotein I antibodies by ELISA. It has been reported that β2-glycoprotein I (β2GPI) changes its conformation from a native to an active form and thereby it opens up enabling antibodies to bind a specific epitope. We amongst others have shown that epitope glycine40-arginine43 of domain I of β2GPI is predominantly responsible for binding thrombosis rel...
Objective It has been suggested that only antibodies against domain 1 (D1) of \u3b22-glycoprotein I ...
As the clinical symptoms of the antiphospholipid syndrome (APS) frequently occur irrespective of the...
OBJECTIVE: It has been suggested that only antibodies against domain 1 (D1) of β2 -glycoprotein I (β...
The antiphospholipid syndrome (APS) is diagnosed by the occurrence of thrombosis and/or specific pre...
The antiphospholipid syndrome (APS) is diagnosed by the occurrence of thrombosis and/or specific pre...
The antiphospholipid syndrome (APS) is diagnosed by the occurrence of thrombosis and/or specific pre...
Beta-2 glycoprotein I (\u3b22GPI) is the main antigenic target for antiphospholipid antibodies (aPL)...
The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidi...
The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidi...
The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidi...
The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidi...
INTRODUCTION: Antiphospholipid Syndrome (APS) is characterized by the presence of circulating antiph...
INTRODUCTION: Antiphospholipid Syndrome (APS) is characterized by the presence of circulating antiph...
INTRODUCTION: Antiphospholipid Syndrome (APS) is characterized by the presence of circulating antiph...
Beta-2 glycoprotein I (\u3b22GPI) is the main antigenic target for anti-phospholipid antibodies (aPL...
Objective It has been suggested that only antibodies against domain 1 (D1) of \u3b22-glycoprotein I ...
As the clinical symptoms of the antiphospholipid syndrome (APS) frequently occur irrespective of the...
OBJECTIVE: It has been suggested that only antibodies against domain 1 (D1) of β2 -glycoprotein I (β...
The antiphospholipid syndrome (APS) is diagnosed by the occurrence of thrombosis and/or specific pre...
The antiphospholipid syndrome (APS) is diagnosed by the occurrence of thrombosis and/or specific pre...
The antiphospholipid syndrome (APS) is diagnosed by the occurrence of thrombosis and/or specific pre...
Beta-2 glycoprotein I (\u3b22GPI) is the main antigenic target for antiphospholipid antibodies (aPL)...
The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidi...
The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidi...
The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidi...
The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidi...
INTRODUCTION: Antiphospholipid Syndrome (APS) is characterized by the presence of circulating antiph...
INTRODUCTION: Antiphospholipid Syndrome (APS) is characterized by the presence of circulating antiph...
INTRODUCTION: Antiphospholipid Syndrome (APS) is characterized by the presence of circulating antiph...
Beta-2 glycoprotein I (\u3b22GPI) is the main antigenic target for anti-phospholipid antibodies (aPL...
Objective It has been suggested that only antibodies against domain 1 (D1) of \u3b22-glycoprotein I ...
As the clinical symptoms of the antiphospholipid syndrome (APS) frequently occur irrespective of the...
OBJECTIVE: It has been suggested that only antibodies against domain 1 (D1) of β2 -glycoprotein I (β...